
The Mental Health Remix: Can MusicTech Help Us Feel Better?
Studies have shown that creative thinking involves the interplay between the brain's executive control network, which is responsible for focus, and the default mode network, which is associated with imagination and mind-wandering. Creative cognition draws on both associative and controlled processes.
Researchers have also found that listening to happy music can enhance divergent thinking, a key part of creativity. One study published in Frontiers for Young Minds showed that enhancing creativity in teens improved their problem-solving abilities. Pursuing creative activities has also been shown to boost scientific learning.
Mike Mantione, singer and songwriter of the punk band Five Eight and The Bad Ends, says that some of his first experiences with music came from playing 45s on a little Victrola he had.
"Songs like "Bridge Over Troubled Water," "Age of Aquarius," "Celia," and "Kodachrome," I'd listen to them over and over again, completely losing myself in them," said Mantione. "Music had a way of letting me almost live inside the song."
Mantione says in high school, he was dealing with what he now recognizes as a free-floating anxiety disorder.
"Then I discovered Quadrophenia, and it blew me away," said Mantione. "It felt like I had found a kindred spirit. Everything felt overwhelming, but somehow, that album made it feel like it might be okay. Just blasting it at full volume immediately lessened the anxiety."
For Mantione, music, especially loud, visceral rock and roll, became a physical and emotional release.
"The dancing, the volume, the immersion—it was like breaking apart the trauma I had carried from my early life," said Mantione. "Music gave me a way to cope with feelings that might've drowned me otherwise. Quadrophenia wasn't just an album—it was a lifeline."
While Mantione's experience is deeply personal, a growing number of companies are working to translate music's emotional impact into measurable health outcomes.
"It's not a stretch to see music as a form of medicine when you think about how it's being integrated into therapeutic environments," said Con Raso, music technologist and CEO of Tuned Global. "But for it to function like a drug, it needs more than emotional resonance—it needs precision in how it's selected, delivered, and measured. That's where technology plays a critical role."
"It's early days, but the trajectory is clear: music is starting to behave more like a treatment protocol than a playlist," said Raso. "But for it to function like a drug, it needs more than emotional resonance—it needs precision in how it's selected, delivered, and measured. That's where technology plays a critical role."
Gary Jones, CEO and co-founder of MediMusic, says music stimulates more parts of the brain than any other stimulus.
"It interacts with the amygdala, the hippocampus, auditory cortex — areas responsible for memory, emotion and sensory processing," said Jones.
"Music lets you step outside the spinning wheel of neurosis and despair," said Mantione. "Even violent punk rock can break up trauma like an earthquake—it shakes everything loose. It reminds you that you're alive."
Jones says MediMusic built on that science with Digital Drip, a system that dynamically generates music that mimics the human brain's natural response to audio cues like tempo, harmony and timbre.
"We're not offering a generic playlist," said Jones. "We're dispensing music in a way that changes heart rate variability, reduces cortisol and encourages the release of dopamine — all measurable biomarkers."
"It's not metaphorical when we call music a digital drug; we mean it in the sense that it's dosed, tracked, and adjusted based on real physiological outcomes," said Jones. 'That's how we're using music to help manage anxiety, chronic pain, and cognitive decline — not just to soothe but to treat.'
When Mantione was 21 years old, he went through a breakdown and voluntarily committed himself to an institution for care.
"Music creates a space where you can be held by something larger than your own pain," said Mantione. "When I went through a breakdown and came out of the hospital, writing music became part of my recovery," said Mantione. "Autobiographical songs—about depression, anxiety, psychosis, fear—gave me a framework to name what I was feeling and then reshape it."
"Songs like "Behind the Glass Wall" (from my pre-Five Eight days) and "In His Own Corner" allowed me to live in those feelings, but in a way that was constructive," said Mantione. "And when you perform those songs, they don't just disappear when the set ends—they stay with you. They echo in your head all day long, like a coping mechanism you can carry around."
Mantione says that when people come out to see Five Eight, he thinks they hear the music as a coping mechanism.
"Songs like "I'm Depressed Almost All the Time," "Suit of Sin," and "The Only One" are brutally honest, but they're also celebrations of survival. We're not wallowing—we're singing through it together. That's healing," said Mantione.
"We've shown in NHS environments that we can reduce anxiety pre-operatively or improve focus in patients with dementia," said Jones. "But it's also the tech itself — our AI dynamically changes music in real-time, responding to biosignals. That's no longer theoretical. It's happening in clinics now."
Jones says breakthroughs in the MedTech space have been the validation of adaptive music as an evidence-based tool and collaborations.
"It's no longer isolated pilots — we're now part of broader initiatives with Tuned Global and others, who help bring this tech to life in complex ecosystems."
While MediMusic focus on precision and biomarkers and provides their solution to music therapists, others in the space are building on the app model to deliver theraputic benefits.
Ariana Alexander-Sefre, CEO of Spoke, believes music will become a standard part of the mental health toolkit—especially for Gen Z, who already turn to it as self-medication.
The Walton Family Foundation reported in 2024 that 42% of Gen Z battles with depression and feelings of hopelessness, nearly double the rate for Americans over 25.
"Pharmaceuticals treat symptoms. Music tech treats the human," said Alexander-Sefre. 'Music harnesses the neuroscience of rhythm, tone and repetition to regulate the nervous system and support emotional processing—without side effects, waitlists, or stigma.'
Spoke combines music and mindfulness prompts to help Gen Z users reach specific mental states. Its artist-created content is guided by clinical psychologists, therapists, and neuroscientists.
'What makes it powerful is its accessibility. It meets people where they are, literally in their ears,' she said.
Alexander-Sefre says Spoke is building towards a future where music isn't just a vibe, it's a regulated, trackable,and effective health intervention. 'As AI personalization evolves, so will the ability to create hyper-tailored, clinically informed music journeys for stress, sleep, anxiety, focus and more,' she said.
Like Spoke, Spiritune uses a science-based approach to design emotionally resonant soundscapes—grounded in clinical neuroscience.
Jamie Pabst, CEO of Spiritune, says MusicTech offers a non-invasive approach to mental health that is scalable, culturally relevant and effective.
Spiritune uses neuroscience and personalization to deliver therapeutic sound experiences—and has secured $1.7 million in funding to scale its science-backed platform.
"With healthcare systems overwhelmed and waitlists growing, we simply can't rely on traditional mental health services alone," said Pabst. 'Music tech provides a culturally relevant, low-barrier solution that people can turn to anytime, anywhere, helping to support both clinical and non-clinical populations.'
Spiritune uses proprietary compositions and AI to guide users from negative states like stress and burnout into more positive states such as calm or determination.
A recent PLOS ONE study found that Spiritune outperformed other audio platforms in reducing negative emotional states—and was the only method that improved processing speed in under ten minutes.
"These results were experienced by 76% of participants," said Pabst. "And in clinical programs where Spiritune is embedded, we've seen a 60% improvement in mental health scores in just three weeks."
But Mantione says that even though technology makes access to music therapy immediate, it should not be over-monetized.
"The key, though, is avoiding the trap of over-monetizing the experience," said Mantione. "Music therapy needs to remain something human. That doesn't mean it can't be digital—it just means the delivery has to respect the vulnerability of the listener. Technology should support the journey, not flatten it."
Mantione adds that tech can also build a community you can rely on.
"You can listen to exactly what you need in the moment you need it. That's huge. But beyond that, tech can also build community," said Mantione. "If someone's isolated or in crisis, they can find not just a song—but a voice, a group, a story that mirrors their own."
Jones says patients deserve more than pills; they deserve holistic care.
"Music offers a non-invasive, evidence-based method to support mental and emotional wellbeing, whether you're managing anxiety, pain, or cognitive disorders," said Jones. "And let's not forget: it's a method patients like. They opt-in, they feel empowered, and they often report benefits quickly."
"That emotional acceptance, combined with physiological impact, is incredibly rare in medicine," added Jones. "And it's why we're investing so deeply in this work."
Behind this wave of innovation is a growing body of neuroscience research—much of which is shaping how these companies design and deliver sound-based therapy.
Rasso says this matters because it opens up a different way to think about care—one that feels more human and intuitive.
"When we talk about using music to ease pain, improve sleep, or reduce stress, we're talking about interventions that can be integrated into people's lives without friction," said Rasso. "And if we can build the systems around that — to deliver it securely, personally, and ethically — then music becomes not just part of entertainment but part of how we live better and feel better."
"It also matters for the music industry and the artists who are working hard to make a living," he said. This gives them other pathways than just having their music played on DSPs like Spotify and Apple Music."
Pabst says neuroscience is Spiritune's backbone.
"Everything we do is rooted in a deep understanding of how the brain and body respond to music," said Pabst. Our foundational team includes neuroscientists and clinicians who inform our research and product development, ensuring that the music we deliver is not only aesthetically pleasing but therapeutically effective."
"We are devoted to continuously analyzing the physiological, behavioral, and cognitive effects of our music to optimize outcomes, and our research partnerships ensure that we stay on the leading edge of music and brain-based therapeutic innovation," said Pabst.
MediMusic's Jones says that for them, the correlation lies in how music affects the nervous system and how MedTech can measure and harness those effects.
"Music triggers neurochemical responses — dopamine, oxytocin, even immunoglobulins — and changes in physiological states like heart rate or skin conductance," said Jones. "MedTech takes that further by embedding music within clinical protocols, measuring outcomes, and refining delivery through data."
"At MediMusic, we've treated this correlation with the same rigor as a pharmaceutical trial — applying for ethics approval, running controlled studies, and working toward digital therapeutics regulation," said Jones. "It's music meeting medicine, backed by evidence, not just feeling."
Mantione says that many people don't take music seriously enough.
"It's seen as entertainment, not treatment," said Mantione. "But if you ask someone to reflect on their life's hardest or most beautiful moments, odds are music was there—fused into the memory."
"I think part of the issue is that people think music therapy has to be clinical or that they're not "musical" enough to benefit from it," said Mantione. "But it's not about talent. It's about connection. It's about honoring the feeling and giving it rhythm and shape. That's where healing begins."
"The connection between music and medicine is obviously strengthening as more companies investigate the therapeutic applications of sound and the need for evidence-based outcomes," said Rasso. "Technological advancements lead to greater integration between content delivery platforms and biometric or behavioral data inputs."
Rasso says this enables the personalization of music to align with therapeutic goals, not just individual preferences. "The aim is not to eliminate emotion from music but to utilize it effectively within a clinical context."
Rasso points to the crucial choice of the music catalog in therapy. "While a back catalog might be suitable for dementia patients, it could be problematic for those with PTSD," said Rasso. "Catalog filtering is key. Biofeedback and real-time data loops can also be employed to identify the impact of music on patients and adjust it accordingly."
"Music has pulled me back from the edge more times than I can count," said Mantione. "It gives structure to feelings that otherwise might consume you. Writing and performing became my way of talking about things I couldn't say out loud. It's shadow work."
Mantione says there's a Hüsker Dü song, "I Will Never Forgive You," hit him like lancing a boil.
"It hurt, but it also released something. That's what music can do," said Mantione. "You integrate the darker parts of yourself through the art—and suddenly, it's not just pain anymore. It's something creative. Something powerful."
"I think about a show I saw in 1982—Black Flag and the Minutemen at SUNY Binghamton," said Mantione. "Watching Henry Rollins explode onstage, in this trance-like fugue state, ripping the skin off his back mid-performance, it was primal. And it mirrored the pain I was carrying."
"Music tech provides a culturally relevant, low-barrier solution that people can turn to anytime, anywhere, helping to support both clinical and non-clinical populations," said Pabst.
Pabst says Spiritune sees MusicTech as a modern therapeutic modality that can achieve outcomes comparable to frontline treatments like drug therapy and talk therapy. "It does thisthrough the emotional resonance of music, guided by the precision of neuroscience."
"For me, music has been a form of shadowwork. I've looked at songwriting as a way to grapple with things that are almost impossible to talk about—taking a common, painful feeling and turning it into a kind of celebration through song," said Mantione. "By integrating the shadow self through art, we can transform trauma, making it something creative and powerful."
"We are entering the age of ambient mental health care, said Alexander-Sefre. "Just as Spotify changed how we listen to music, music tech is changing how we experience wellbeing."
"Imagine streaming platforms that adapt to your emotional state in real-time, playlists that function like therapeutic interventions, or artist-led mental health content that doesn't feel like therapy but works like it," she added.
For artists like Mantione, that future is already personal. What the industry is working to build, he's lived—song by song.
"If you're a person in pain, music doesn't have to "fix" you. It just has to meet you where you are," said Mantione. "For me, it's never been about being cured. It's about staying connected—to the music, to the people, to the part of myself that still wants to fight to stay here."
"And if you're lucky, you find other people who feel the same way and sing along," said Mantione.
____
Five Eight's first song in six years, 'Take Me To The Skatepark', is available on Spotify. Their documentary, Weirdo: The Story of Five Eight, is playing at indie film and music festivals around the country.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hamilton Spectator
22-07-2025
- Hamilton Spectator
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau. 'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.' Key Scientific Sessions and Presentations: Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on , building on the resources already available. For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth. About BIIB080 BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis. About LEQEMBI ® (lecanemab) LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide . About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at . Follow us on social media - Facebook , LinkedIn , X , YouTube . Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.


Business Upturn
22-07-2025
- Business Upturn
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau. 'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.' Key Scientific Sessions and Presentations: Lecanemab Clarity AD OLE in Early AD: Initial Findings from 48-Month Analysis Wednesday, July 30, 8:00–8:45 AM ET Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's Disease Wednesday, July 30, 9:00–10:30 AM ET Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery Sunday, July 27, 8:00–8:45 AM ET Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway Learnings Sunday, July 27, 9:00–10:30 AM ET Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results Sunday, July 27, 4:14–5:45 PM ET Innovations in Tau Therapies and Biomarkers for Alzheimer's Disease: Bridging Research and Clinical Practice Wednesday, July 30, 2:00–3:30 PM ET Baseline Characteristics from CELIA: A Phase 2 Study to Evaluate BIIB080 in Participants with Early Alzheimer's Disease Monday, July 28, 7:30 AM–4:15 PM ET Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on building on the resources already available. For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth. About BIIB080 BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis. About LEQEMBI ® (lecanemab) LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at Follow us on social media – Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


USA Today
29-06-2025
- USA Today
Paul Simon cancels shows due to 'intense' back pain that 'demands immediate attention'
Paul Simon has scrapped a pair of shows and will undergo a surgical procedure due to "intense" back pain. The legendary Simon & Garfunkel singer, 83, shared in a statement on Instagram that he has canceled his performances set for Saturday, June 28, and Sunday, June 29, at Philadelphia's Academy of Music. "Paul has been struggling with chronic and intense back pain," the statement said. "Today it became unmanageable and demands immediate attention. Unfortunately we have to cancel these shows at this time, as we don't have the ability to reschedule them." Simon's announcement said that he will undergo a "minor surgical procedure" in the next few days but that he is "hopeful" he will be able to complete his tour and make up the Philadelphia shows. Refunds for the performances are available at the point of purchase. The "Bridge Over Troubled Water" hitmaker is currently in the middle of his A Quiet Celebration tour. He completed a farewell tour in 2018 but announced his return in February, fresh off an appearance on the 50th anniversary special of "Saturday Night Live" with Sabrina Carpenter. Paul Simon returns to touring after 7-year hiatus and 2018 retirement According to his February tour announcement, Simon, "who has been dealing with severe hearing loss," chose "intimate venues with optimal acoustics" for the shows, which began in New Orleans in April and will conclude in August in Seattle, Washington. Paul Simon, graceful poet and musical genius, gets his documentary due 'In Restless Dreams' In a June appearance on "The Late Show with Stephen Colbert," the 16-time Grammy winner explained he previously "didn't think it was possible for me to be able to perform again with other musicians" due to his hearing loss. Simon is next scheduled to perform in Long Beach, California, on July 7, according to his website. He then has more shows scheduled throughout July in California before he's off to Vancouver and Seattle.